Filing Flows › Comparisons › RNA vs TRAW
Atrium Therapeutics vs Traws Pharma: RNA and TRAW compared
Atrium Therapeutics is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.7M for Traws Pharma (Q2 2025). Traws Pharma is growing faster (48× against -22% a year earlier). Traws Pharma is more profitable, with an operating margin of -45.7% against -752.9%.
Where the money goes: RNA and TRAW
Atrium Therapeutics (RNA) · Q2 2026
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Traws Pharma (TRAW) · Q2 2025
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Atrium Therapeutics (RNA) | Traws Pharma (TRAW) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2025 |
| Revenue | $3.0M | $2.7M |
| Revenue growth, Y/Y | -22% | 48× |
| Operating margin | -752.9% | -45.7% |
| Net earnings | −$20.2M | −$915K |
| Net margin | -672.0% | -33.5% |
| Operating cash flow | −$3.9M | −$6.0M |
Questions
Which is bigger, Atrium Therapeutics or Traws Pharma?
Atrium Therapeutics is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.7M for Traws Pharma (Q2 2025).
Is Atrium Therapeutics or Traws Pharma growing faster?
Traws Pharma is growing faster (48× against -22% a year earlier).
Which is more profitable, Atrium Therapeutics or Traws Pharma?
Traws Pharma is more profitable, with an operating margin of -45.7% against -752.9%.
More: Atrium Therapeutics earnings · how Atrium Therapeutics makes money · Traws Pharma earnings · how Traws Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2025). Fiscal quarters can end on different dates. Not investment advice.